The diverse effects mediated by PI3K/PTEN (phosphoinositide 3-kinase/phosphatase and tensin homologue deleted on chromosome 10) signalling in the heart clearly support an important biological and pathophysiological role for this signalling cascade. PI3Ks are a family of evolutionarily conserved lipid kinases that mediate many cellular responses to physiological and pathophysiological stimuli. Class I PI3K can be activated by either receptor tyrosine kinase/cytokine receptor activation (class I A ) or Gprotein-coupled receptors (class I B ), leading to the generation of phosphatidyl inositol (3,4,5)P 3 and recruitment and activation of Akt/protein kinase B, 3 0 -phosphoinositide-dependent kinase-1 (PDK1), or monomeric G-proteins, and phosphorylation of a wide range of downstream targets including glycogen synthase kinase 3b (GSK3b), mTOR (mammalian target of rapamycin), p70S6 kinase, endothelial nitric oxide synthase, and several anti-apoptotic effectors. Class I A (PI3Ka, b, and d) and class I B (PI3Kg) PI3Ks mediate distinct phenotypes in the heart under negative control by the 3 0 -lipid phosphatase PTEN, which dephosphorylates PtdIns(3,4,5)P 3 to generate PtdIns(4,5)P 2 . PI3Ka, PI3Kg, and PTEN are expressed in cardiomyocytes, fibroblasts, endothelial cells, and vascular smooth muscle cells, where they modulate cell survival, hypertrophy, contractility, metabolism, and mechanotransduction. The PI3K/PTEN signalling pathways are involved in a wide variety of diseases including myocardial hypertrophy and contractility, heart failure, and preconditioning. In this review, we discuss the signalling pathways mediated by PI3K class I isoforms and PTEN and their roles in cardiac structure and function. KEYWORDS P13 kinase; Akt; Signalling; Hypertrophy; Heart failure 1. Structure and function of phosphoinositide 3-kinases Phosphatidylinositols (PtdIns) are phospholipids that comprise a phosphoglyceride esterified to the hydroxyl group of an inositol ring which can be phosphorylated and dephosphorylated at various positions by lipid kinases and phosphatases, respectively.
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P13 kinase; Akt; Signalling; Hypertrophy; Heart failure 1. Structure and function of phosphoinositide 3-kinases Phosphatidylinositols (PtdIns) are phospholipids that comprise a phosphoglyceride esterified to the hydroxyl group of an inositol ring which can be phosphorylated and dephosphorylated at various positions by lipid kinases and phosphatases, respectively. [1] [2] [3] [4] Phosphatidylinositol-4,5-phosphate [PtdIns(4,5)P 2 ] is the main precursor for PtdIns(3,4,5)P 3 biosynthesis by class I PI3K enzymes which are activated by a range of agonists. 1, 3, 5, 6 PtdIns(3,4,5)P 3 is degraded by the lipid phosphatases, PTEN (phosphatase and tensin homologue deleted on chromosome 10) and SHIP2 (and SHIP1), functioning effectively as 3 0 -and 5 0 -phosphatases to generate PtdIns(4,5)P 2 and PtdIns(3,4)P 2 , respectively. 3, 4, 7 Phosphoinositide 3-kinases (PI3Ks) and PTEN are the primary regulators of PtdIns(3,4,5)P 3 and PtdIns(3,4)P 2 [and PtdIns(4,5)P 2 ] levels, which in turn mediate selective targeting and activation of many downstream effectors by binding to selective domains such as the pleckstrin homology (PH) domain. 3, 4, 8 The PH domain has a unique three-dimensional structure with an affinity for PtdIns (3, 4, 5 )P 3 that is two orders of magnitude greater than for other phosphorylated PtdIns. 3, 8 PI3Ks are classified on the basis of their substrate specificity, mode of activation, and molecular structure. 1, 3, 5, 6 Class I A and I B PI3Ks are heterodimeric enzymes composed of a regulatory adaptor (accessory) subunit coupled to a catalytic subunit. 3, 5, 6 Class I A catalytic subunits include p110a, p110b, and p110d, whereas the class I B catalytic subunit is p110g 3, 6 ; however, more recent data suggest that p110b may also effectively couple to G-protein-coupled receptors (GPCRs) and therefore could function as a class I B catalytic subunit. 9, 10 The class 1 A PI3K adaptor (accessory) subunits are encoded by three genes which generate highly homologous products, p85a (85 kDa) (pik3r1), p85b (85 kDa) (pik3r2), and p55g (55 kDa) (pik3r3), with p85a being the predominant isoform in the heart. 3, 6, 11, 12 The class I B PI3K adaptor (accessory) subunit (p101) is tightly associated with the catalytic subunit p110g. 3, 6, 13 Class I PI3Ks phosphorylate PtdIns, PtdIns(4)P and PtdIns(4,5)P 2 , to form PtdIns(3)P, PtdIns(3,4)P 2 , and PtdIns(3,4,5)P 3 in vitro, respectively, whereas phosphorylation of PtdIns(4,5)P 2 to form PtdIns(3,4,5)P 3 is the predominant in vivo response to agonist stimulation. 1, 3, 6, 13 All catalytic subunits of class I PI3Ks contain four conserved homology domains (HDs) (from N-to C-terminus): Rasbinding domain (RBD or HR4), C2 domain (HR3), PIK (helical) domain (HR2), and the catalytic kinase domain (HR1). 3, 4, 6 The RBD binds the monomeric G-protein, Ras, whereas the C2 and PIK (helical) domains are involved in phospholipid membrane binding and protein/protein interaction, respectively. The p110g subunit also contains two G bg interaction sites, located in the N-terminal p101-binding and C-terminal catalytic domains which are critical for GPCR-mediated signalling. 6 The p110a and b isoforms are expressed in the heart and vasculature, 6, 12, 14 whereas p110g is expressed in cardiomyocytes, 12, 15 cardiac fibroblasts, 4 vascular smooth muscle cells (VSMCs), 16 and endothelial cells. 17, 18 Adaptor (accessory) proteins have an expression pattern which mirrors their corresponding catalytic subunits and bind their catalytic subunits via p110-binding regions. [3] [4] [5] [6] Class I A adaptor p110-binding domains are flanked by two Src-homology 2 (SH2) domains which upon receptor stimulation bind to phosphotyrosines in the activated receptor allowing the class I A PI3K heterodimer to phosphorylate lipid substrate(s) in membranes. [3] [4] [5] [6] 19 Phosphotyrosine docking sites are created by autophosphorylation in response to receptor tyrosine kinase (RTK) or Janus-activated kinase activation. 6, 19 In contrast to class I A PI3Ks, p110g binds G bg subunits following GPCR stimulation, leading to translocation from the cytosol to the cell membrane and kinase activation. 6, 13, 20 This activation of p110g by GPCR stimulation is amplified by simultaneous binding of G bg subunits to the p101 adaptor subunit. 6 Catalytic activities of both class I A and I B PI3Ks are further increased by conformational changes and membrane reorientation of the catalytic domains induced by interaction between the RBD and guanosine triphosphate-bound monomeric G-protein Ras. 4 In addition to lipid kinase activity, class I PI3K catalytic subunits have intrinsic protein kinase activity in vitro, which can lead to autophosphorylation of both catalytic and adaptor subunits as well as activation of MAPK. 3, 21 2. Structure and function of PTEN: a 3 0 lipid phosphatase and a negative regulator of phosphoinositide 3-kinases PTEN is a 3 0 -lipid phosphatase and is also known as 'mutated in multiple advanced cancers' (MMAC1) and TGFb-regulated and epithelial cell-enriched phosphatase (TEP1). 7, 22 Mammalian PTEN has a molecular weight of 40-50 kDa and comprises an N-terminal PIP 2 -binding polybasic tail, an N-terminal phosphatase domain, a C2 domain, and a Cterminal tail region that contains the PSD-95/Dlg/ZO-1 (PDZ) HD as well as multiple phosphorylation sites. 7, 22 Dephosphorylation of focal adhesion kinase and the adaptor protein Shc by PTEN leads to inhibition of cell migration, suggesting that PTEN may exhibit some protein phosphatase activity. 3, 7, 23 However, PTEN functions predominantly as a 3 0 -lipid phosphatase in vivo 12, 24 owing to its unique catalytic site allowing accommodation of the bulky acidic PtdIns(3,4,5)P 3 substrate. 7, 22 The main physiological substrate of PTEN is membrane-bound PtdIns(3,4,5)P 3 , and activation of PTEN involves recruitment to the plasma membrane in part due to its high anionic lipid content. 25 The polybasic N-terminal region, catalytic and C2 domains of PTEN are involved in electrostatic binding to PtdIns(4,5)P 2 and spatial orientation of PTEN. 22, 25, 26 However, phosphorylation of C-terminal cationic residues maintains PTEN in an inactive state until dephosphorylation of PTEN triggers targeting to the plasma membrane via electrostatic interactions between the dephosphorylated C-terminal residues and PtdIns, followed by recruitment into a proteinassociated complex involving its PDZ-binding domain. 22, 25, 27 Allosteric activation of PTEN by its substrate, PtdIns(4,5)P 2 , provides an additional mechanism for regulating PTEN activity independent of membrane binding. 27 In addition, PTEN can be found in the nucleus, where it has a distinct role from cytoplasmic PTEN. 28 PTEN is also sensitive to the cellular redox status by the modification of cysteine residues in the active site, 22, 29 whereas certain agonists induce changes in the expression of PTEN by both transcriptional and translational mechanisms. 4 Antagonistic actions of PTEN on PI3K signalling is evolutionary-conserved and occurs in various mammalian tissues including the heart. 4, 12 Overexpression of catalytically active PTEN decreases basal and insulin-stimulated PtdIns(3,4,5)P 3 levels, 7 whereas overexpression of wild-type PTEN into PTEN-null cell lines causes a decrease in intracellular levels of PtdIns(3,4,5)P 3 [and PtdIns(3,4)P 2 ]. 4, 7 In contrast, in embryonic stem cells lacking PTEN, PtdIns(3,4,5)P 3 levels are increased 24 with greater insulinlike growth factor-1 (IGF-1)-induced accumulation of PtdIns(3,4,5)P 3 , 30 whereas expression of a catalytically inactive PTEN causes increased cellular PtdIns(3,4,5)P 3 levels. 7 PTEN is widely expressed in many cells including cardiomyocytes, 12, 31 VSMCs, and endothelial cells. 4, 32 3. Molecular targets of phosphoinositide 3-kinase and PTEN signalling 3.1 Phosphoinositide-dependent kinase-1
Phosphoinositide-dependent kinase-1 (PDK1) is a ubiquitously expressed 67 kDa kinase containing an N-terminal catalytic domain and a C-terminal PH domain. 4, 33 PDK1 phosphorylates and activates a number of kinases including Akt/PKB, protein kinase C, serum and glucocorticoidregulated kinase-1 (SGK1), and p70S6-kinase (p70S6K). 4, 33 Cardiac-specific PDK1 ablation leads to reduced cardiomyocyte size and cardiomyopathy ( Table 1) . 34 
Akt/protein kinase B
Akt/protein kinase B (PKB) is a serine/threonine protein kinase family comprising three closely related members: Akt1 (PKBa), Akt2 (PKBb), and Akt3 (PKBg). 4, 35, 36 Akt/PKB contains an N-terminal PH domain, a central catalytic domain, and a C-terminal regulatory domain. 35, 36 The activity of Akt/PKB is primarily controlled by PI3K and PTEN via the modulation of PtdIns(3,4,5)P 3 levels. 3, 7, 12, 24 In mammalian cells, full activation of Akt/PKB activation occurs through a sequential two-step process involving recruitment of Akt/PKB to the plasma membrane via its PH domain, followed by phosphorylation of a threonine residue (threonine-308) 4, 34 in the catalytic domain by PDK1 and a serine residue (serine-473) in the C-terminal regulatory domain by the rictor-mTOR complex (mTOR complex 2). 37 Akt/PKB is directly inactivated following dephosphorylation of the two regulatory sites by the serine-threonine phosphatase, protein phosphatase 2A (PP2A). 38 Akt/PKB controls a variety of regulatory responses in mammalian cells, including inhibition of apoptosis and regulation of cellular proliferation, metabolism, and hypertrophy 4, 36, 38, 39 and is activated by both RTKs/ cytokines [4] [5] [6] 35, 39 and GPCRs. 4, 6, 12, 35 Activated Akt/PKB phosphorylates several downstream targets including glycogen synthase kinase 3b (GSK3b), mammalian target of rapamycin (mTOR), endothelial nitric oxide synthase (eNOS or NOS3), 6-phospho-fructo-2-kinase (PFK2), c-Raf (a serine/ threonine kinase), and several anti-apoptotic effectors within the cytoplasmic, mitochondrial, and nuclear compartments. 4, 36, 39, 40 All three known Akt/PKB family members are expressed in the myocardium, with the Akt1/ PKBa and Akt2/PKBb isoforms being the most abundant ( Table 1) . 12, 35, 41, 42 Following the recruitment and activation of Akt/PKB at the plasma membrane, activated Akt/PKB exerts multi-compartmental effects in the nuclear, cytoplasmic, and mitochondrial compartments, 4, 43, 44 which may explain the phenotypic diversity observed with targeted overexpression of the different Akt/PKB constructs ( Table 1) . [45] [46] [47] [48] [49] 3.3 Glycogen synthase kinase-3 GSK3 is a serine/threonine kinase which was originally identified to phosphorylate and inactivate glycogen synthase.
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GSK3 has two mammalian isoforms: GSK3a and GSK3b, which are both expressed in the heart. 12, 40, [50] [51] [52] GSK3b is constitutively active in unstimulated cells, where it phosphorylates several targets in addition to glycogen synthase, including cyclin D, c-Jun, NFAT, and the canonical Wnt/b-catenin, leading to their inactivation and/or degradation. 40 Cardiac-specific overexpression of GSK3b is associated with reduced agonist and pressure-overload-induced hypertrophy, confirming that GSK3b functions as a negative regulator of hypertrophy in vivo ( Table 1) . 51, 53, 54 GSK3a and GSk3b are both present in the cytoplasmic and nuclear compartments, where they can mediate distinct physiological effects. 40, 52 For example, cytoplasmic GSK3b phosphorylation of the canonical Wnt/b-catenin leading to its degradation may modulate N-cadherin/b-catenin cell adhesion complexes, whereas the nuclear effects of GSK3b phosphorylation of NFAT may relate to its anti-hypertrophic effects. 40, 51, 52 In response to RTK/GPCR activation, phosphorylation of serine-9 residue in the N-terminal region of GSK3b by Akt/PKB inhibits GSK3b, thereby leading to diverse effects including improved cell survival and hypertrophy 40, [51] [52] [53] possibly resulting from the upregulation of calcineurin/NFAT and c-Jun NH 2 -terminal kinases (JNKs). 51, 53 In contrast, GSK3a is phosphorylated at the serine-21 residue by Akt/PBK, which plays a compensatory role in the setting of pathological hypertrophy possibly by the inhibition of ERK1/2 signalling. 52 3.4 Mammalian target of rapamycin and p70 S6 kinase mTOR, also termed FRAP (FKBP-12 rapamycin-associated protein), is a 289 kDa evolutionary-conserved serine/threonine kinase that is inhibited by the drug rapamycin. 4, 55, 56 RTK and Akt/PKB activation as well as elevated amino acids activate mTOR via both translational and phosphorylation-dependent mechanisms leading to altered metabolism and increased growth mediated by changes in gene transcription and translation. 4, 55 For example, mTOR phosphorylates and thereby inactivates the eukaryotic translation initiation factor called 4E-binding protein 1 (4E-BP1) leading to increased protein translation. 4 ,56 mTOR also phosphorylates and activates p70S6K, which is a short isoform of the ribosomal S6 kinase (S6K1). 55 Ribosomal S6 kinases (S6K1 and S6K2) are key regulators of cell growth through the control of protein translation particularly for mRNA transcripts containing polypyrimidine sequences at the transcriptional start site by phosphorylating the S6 protein of the 40S ribosomal subunit. 57 Both mTOR and p70S6K are expressed in the heart and VSMCs. 12, 58 Whereas the whole-body knockout of p70S6K is associated with reduced somatic growth, 59 loss of S6K1 and/or S6K2 has no impact on the development of physiological, pathological, or PI3K-mediated cardiac hypertrophy, suggesting that S6K is a redundant hypertrophy pathway ( Table 1) . 60 4. Cardiac effects of phosphoinositide 3-kinase and PTEN signalling
Cell survival
Activation of PI3K enhances cell survival and antagonizes apoptosis via Akt/PKB activity in many cell types including cardiomyocytes, cardiac fibroblast, VSMCs, and endothelial cells. 4 The anti-apoptotic action of Akt/PKB involves both cytoplasmic and nuclear compartments via modulation of Bad, caspase-3, forkhead transcription factors, and IkB kinase. 4, 43 Growth factors that reduce apoptosis such as insulin, IGF-1, erythropoietin, and cytokines rely almost exclusively on the PI3K/Akt pathway, whereas GPCR-induced PI3K/Akt activation and cardioprotection occur in response to several peptide agonists including urocortin, ghrelin, and adrenomedullin as well as b 2 -AR stimulation. 4, 43, 61, 62 Consistent with the biochemical effects of Akt/PKB, overexpression of Akt/PKB in the heart causes resistance to apoptosis, 4 whereas knockout of Akt2/PKBb enhances apoptosis in response to myocardial ischaemia. 41 Consistent with a critical role for Akt/PKB in cell survival, loss or gain of PTEN activity leads to reduced or enhanced apoptosis, respectively, 63 whereas increased expression of PTEN induces an expected increase of apoptosis in neonatal cardiomyocytes. 31 
Myocardial hypertrophy
PI3K activity is essential for both basal cell growth and adaptive (physiological) and maladaptive (pathological) hypertrophy. 4, 12, 15, [64] [65] [66] [67] PI3K inhibitors attenuate basal rates of protein synthesis and abolish increases in protein synthesis induced by insulin in neonatal cardiomyocytes. 68 Cardiacspecific overexpression of constitutively active PI3Ka (CA-PI3Ka) in mice results in enlarged hearts owing to increased cardiomyocyte size, whereas overexpression of dominant-negative PI3Ka (DN-PI3Ka) produces smaller hearts with reduced cardiomyocyte size without affecting cell number. 12, 64, 66 These changes in heart size are associated with corresponding alterations in Akt/PKB and p70S6K phosphorylation and activities, thereby providing evidence that PI3Ka activation regulates adaptive (physiological) growth and hypertrophy. 4, 12, 64, 66, 69 Indeed, PI3Ka plays a critical role in adaptive growth in response to various physiological stimuli including exercise and IGF-1 via increased phospho-Akt/PKB and p70S6K levels and activities. 42, 64, 66 Activation of cardiac PI3Ka during chronic exercise training is important for maintaining heart structure and function in various pathological settings and may explain the beneficial effects of exercise in patients with heart failure. 69 Moreover, cardiac-specific overexpression of IGF-1 receptor in mice leads to a similar phenotype as the CA-PI3Ka transgenic mice 64, 66 Consistent with a central role of Akt/ PKB in mediating hypertrophy, overexpression of CA-Akt or DN-Akt results in mice with larger or smaller hearts, respectively. 4, 45 Enhanced Akt/PKB activity was associated with increased p70S6K activity and increased phospho-GSK3b, 45 whereas reduced Akt/PKB activity decreases p70S6K activity. 45 The hypertrophy driven by enhanced PI3Ka (and Akt/PKB) activity results in a unique foetal gene expression profile without altering the relative dimensions of cardiomyocytes unlike the changes seen in concentric (reduced long/short axis) and eccentric (increased long/short axis) pathological hypertrophy. 12, 64 Consistent with the biochemical effects of Akt/PKB, overexpression of Akt/PKB in the heart causes hypertrophy and resistance to apoptosis, 45, 46 whereas knockout of Akt1/PKBa attenuates normal physiological growth while promoting pathological myocardial hypertrophy ( Table 1) . 42, 70 The Akt1/PKBa-mediated suppression of pathological hypertrophy may occur owing to Akt1/PKBa antagonism of signalling via ERK1/2 and JNK1/2 pathways while also preventing the antihypertrophic effects of GSK3b. 41, 42 Inactivation of PTEN increases cell size and growth by amplifying PI3K signalling, whereas overexpression of PTEN inhibits PI3K signalling, resulting in decreased cell size. 4, 63 Expression of DN-PTEN in neonatal cardiomyocytes activates Akt/PKB, increases protein synthesis and cell size, although overexpression of wild-type PTEN impaired these responses. 31 Conditional knockout of cardiac PTEN increases myocardial levels of phospho-Akt/ PKB (serine-473), phospho-GSK3b (serine-9), and phospho-p70S6K (threonine-412), resulting in increased cardiomyocyte and heart size. 12 Although PI3Ka/Akt appears to control physiological growth during development, PI3Kg/Akt activation following GCPR stimulation typically leads to pathological (maladaptive) hypertrophy, 4, 15, 65, 67, 71, 72 which may explain the increased PI3K/Akt activity observed in various models of cardiac pathological hypertrophy induced by pressure-overload, Fas-ligand, and chronic b-adrenergic stimulation. 15, 65, 71 Indeed, pressure-overload selectively activates p110g without affecting p110a in the setting of pathological hypertrophy. 65 Various GPCR agonists (G aq ) such as Ang-II, endothelin-1 and a-AR and b-AR agonists lead to PI3K/Akt activation and hypertrophy, 4 whereas loss of PI3Kg prevents activation of Akt/PKB and ERK1/2 pathways in response to b-AR stimulation, resulting in a marked reduction in hypertrophy. 15 Several downstream signalling pathways from Akt/PKB appear to mediate this pathological (maladaptive) hypertrophy including GSK3b 53, 54 and mTOR. 58 Consistent with the key role of PTEN as a negative regulator of the PI3K system, loss of myocardial PTEN enhances the pathological hypertrophy and activation of MAPK in response to the GPCR agonist Ang-II. 23 
Myocardial contractility: cAMP and b-adrenergic signalling
Under basal conditions and following b-AR stimulation, cAMP levels in cardiomyocytes are regulated in a complex manner by interaction between adenylate cyclase-induced synthesis and phosphodiesterase-mediated degradation in welldefined microdomains. 72, 73 Protein kinase A (PKA) is the main effector of cAMP in cardiomyocytes and mediates positive chronotropic, inotropic, and lusitropic effects via phosphorylation of many target proteins involved in excitation-contraction coupling including phospholamban (PLN). 74 Loss of PI3Kg increases basal myocardial cAMP levels without affecting the maximal forskolin-induced cAMP levels 12, 67, 71 and myocardial expression of adenylate cyclase. 15 Loss of PI3Kg appears to reduce PDE4 activity in subcellular compartments containing the SR Ca 2þ -ATPase but not RyR2 or L-type Ca 2þ channels (LTCCs), 72, 75 leading to increased phospho-PLN (serine-16) at baseline, which is consistent with the ability of PDEs to spatially restrict the actions of cAMP in the heart ( Figure 1B) .
12,72 Consistent with these biochemical changes, loss of PI3Kg is associated with sustained increases in contractility and relaxation both in vivo and in single cardiomyocyte without pathological hypertrophy or increased interstitial fibrosis ( Table 1) . 12, 72 In contrast, loss of PTEN leads to reduced cAMP levels in cardiomyocytes, which is rescued by the pharmacological inhibition of PI3K and is associated with reduced myocardial contractility and relaxation.
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PI3Kg also modulates b 2 -AR signalling by confining and reducing b 2 -AR/G as -mediated elevation in cAMP levels and PKA activation but not affecting b 1 -AR stimulation-induced cAMP generation. 12, 76 Indeed, PI3Kg ablation selectively increases cAMP levels, PLN-phosphorylation on serine-16, as well as positive inotropic and lusitropic effects mediated by b 2 -AR stimulation without affecting b 1 -AR effects possibly owing to interactions between b 2 -AR/G ai and PI3Kg, resulting in the modulation of cAMP generation. 4, 12, 72, 76 Interaction between PI3Kg with other GPCRs may also regulate myocardial contractility such as activation of purinergic receptor (P2 receptors) diminishing Ca 2þ oscillations via PI3Kg in neonatal cardiomyocytes, whereas the negative inotropic effects of platelet activating factor, a GPCR agonist released during ischaemia, is completely dependent on PI3Kg.
4,77 PI3K might also regulate myocardial contractility by mediating downregulation of b-ARs in response to agonist stimulation. 71, 78 In response to agonist stimulation, bARK1 (GRK2) mediates PI3K translocation to b-AR, thereby triggering recruitment of phosphoinositide-binding endocytic proteins such as b-arrestin and AP-2, ultimately leading to b-AR internalization. 71, 78 Loss of PI3Kg does not prevent downregulation of b 1 -AR and b 2 -AR in response to chronic b-AR stimulation in vivo. 15, 71 Rather, cardiacspecific overexpression of inactive p110 catalytic subunit (PI3K inact ) prevented b-AR desensitization following chronic b-AR stimulation, suggesting that both PI3Ka and PI3Kg are involved in b-AR desensitization. 71 Despite in vitro evidence showing that PTEN inhibition facilitates b-AR downregulation, neither basal b-AR density and agonist affinity nor bARK1 (GRK2) activity is altered in the hearts of PTEN knockout mice. 12 Although PI3Kg regulates myocardial contractility, PI3Ka (and Akt/PKB) can also influence myocardial contractile strength. Cardiac-specific and temporally controlled overexpression of PI3Ka results in increased myocardial contractility owing to increased expression of multiple Ca 2þ -regulating proteins without resulting in cardiac hypertrophy ( Table 1) . 79 Cardiac-specific expression of IGF-1 receptor and knockout of insulin receptor result in enhanced and reduced myocardial contractility, respectively, whereas IGF-1 induces a positive inotropic effect in cardiomyocytes. 4, 80 Cardiac-specific overexpression of CA-Akt induces variable effects on myocardial contractility, including enhanced (E40K-Akt mutant), 46 preserved (myr-Akt mutant), 47, 48 and reduced (T308D-and S473D-Akt mutants) contractility, 45 which may be related to the differential subcellular targeting of CA-Akt and/or differences in transgene expression ( Table 1) .
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Electrophysiology
PI3Ks can modulate electrical (and contractile) function in the heart by regulating several ion channels/exchanger. 4 IGF-1, a potent activator of PI3Ka and Akt/PKB, induces positive inotropic effects in human ventricular myocytes, which is linked to increased I Ca.L . 80, 81 Although the mechanism for the increase in I Ca,L is unclear, cardiac I Ca,L is increased in transgenic mice with cardiac-specific overexpression of Akt/PKB, suggesting that Akt/PKB might directly phosphorylate LTCCs as do protein kinase A and protein kinase C. 49 Indeed, loss of PTEN results in increased cardiac I Ca,L owing to Akt/PKB-mediated upregulation of LTCC activity via the PI3Ka pathway. 81 Alternatively, Akt/ PKB phosphorylation and extranuclear localization of AHNAK (at serine 5535) into the T-tubular/intercalated disk region regulate F-actin interaction with the b 2 subunit of LTCC, which may affect I Ca,L . 82, 83 The Akt/PI3K system is also involved in the rapid recovery and rebound activation of I Ca,L following acetylcholine-mediated cholinergic stimulation. 84 The inward rectifier family of cardiac K þ channels also appears to be regulated by the PI3K system. PtdIns(4,5)P 2 interaction with Kir2.x (I K1 ) inward rectifier K þ channels promotes subunit assembly and enhances ion channel opening, whereas activation of cardiac phospholipase C and PI3K can lead to local depletion of PtdIns(4,5)P 2 , thereby reducing channel activity. 4 These effects may explain the loss-of-function phenotypes for several mutations associated with Andersen's syndrome (LQT7) involving altered interaction between PtdIns(4,5)P 2 and cardiac Kir2.1. 85 Cardiac Kir3.x (I KAch ) channels are activated by M2 receptors (G ai ) which mediate acetylcholine-negative chronotropic effects and are strongly modulated by PtdIns(3,4,5)P 3 , suggesting a role for PI3Kg via M2 receptor-mediated activation of G bg . 4 Akt/PI3K increases HERG (human ether-a-go-go) current, which encodes for the rapid component of delayed rectifier K þ current (I Kr ), suggesting that voltage-gated K þ channels can also be regulated by the Akt/PI3K system. 86 
Metabolism and mechanotransduction
PI3K plays an important role in myocardial metabolism 47, 87, 88 and mechanotransduction. 23, 89, 90 Activation of RTK (e.g. insulin and epidermal growth factor) or GPCR (e.g. a-and b-AR agonists) promotes glucose uptake via translocation of insulin-responsive glucose transporters (GLUT4) to the plasma membrane in an Akt/PI3K-dependent manner. 4, 41, 91 Enhanced glucose uptake following PI3K activation as a consequence of increased myocardial contraction may increase cardiac glycogen synthesis owing to Akt/ PKB-mediated inhibition of GSK3b as shown in skeletal muscle. 40, 91 Akt/PKB activation also decreases a-AMPactivated protein kinase (a-AMPK) activity, a key determinant of cardiac energy substrate utilization and preference especially in response to insulin 87 while stimulating mTOR activity which senses changes in amino acid levels and regulates protein synthesis. 4, 55 Akt2/PKBb, but not Akt1/PKBa, is required for insulin-stimulated glucose uptake and metabolism. 41 Although Akt2/PKBb negatively regulates fatty acid uptake and metabolism, 41 activation of PI3Ka is sufficient to increase myocardial fatty acid oxidation, a characteristic response seen in physiological hypertrophy, independent of the Akt/PKB pathway. 88 Mechanotransduction plays a fundamental role in cardiac (and vascular) function and involves interaction between extracellular matrix and intracellular cytoskeletal proteins via cell adhesion complexes which are modulated by both class I A and I B PI3Ks. 23, 39, 89, 90 Phosphorylated PtdIns bind and activate several cell adhesion proteins, including gelsolin and profilin, via basic residues, thereby fostering connections between the sarcolemmae and the intracellular actin cytoskeleton. 4, 39 Although PI3K and lipid phosphatases can modulate cytoskeletal interactions, mechanical stretch activates Akt/ PKB and GSK3b activity in both cardiomyocytes and Langendorff-perfused hearts. 92 Consistent with the role of PI3K, lipid phosphatases including PTEN can also regulate many key mediators of cell-matrix adhesion and migration, 4, 89 and loss of myocardial PTEN attenuates the development of heart failure in response to biomechanical stress. 23 
Coronary angiogenesis
Coronary neoangiogenesis occurs during physiological hypertrophy in response to angiopoietin-2 and VEGF-A in order to maintain a balance between myocardial mass and coronary blood flow, whereas vascular rarefaction in the setting of pathological hypertrophy may cause tissue hypoxia and lead to contractile dysfunction. 93, 94 The Akt/PKB-induced expression of angiogenic growth factors such as VEGF maintains coronary angiogenesis and vascular homeostasis in the setting of cardiac hypertrophy and is dependent on the mTOR pathway. 94 Endothelial progenitor cells (EPCs) which are recruited to ischaemic regions leading to neovascularization is under control by PI3Kg. 18 Increased basal angiopoietin-2 and VEGF levels in the setting of basal 'physiological' hypertrophy in PTEN KO mice allowed for normal angiogenesis to maintain coronary capillary density, an important component of physiological hypertrophy. 23, 94 The differential expression of pro-angiogenic factors in cardiomyocyte vs. endothelial-specific knockout of PTEN indicates that cardiomyocyte Akt/PKB signalling is the primary determinant of increased VEGF-A and Ang-II expression. 23, 32 5. Isoform-specific signalling by class I phosphoinositide 3-kinases Cell signalling involves spatial and temporal integration of multiple signalling pathways including PI3K/PTEN signalling, which is spatially and functionally restricted in many cell types including cardiomyocytes and fibroblasts. 4, 95 Physiological growth is regulated via spontaneous and/or agonist-induced (e.g. insulin, IGF-1, and basic fibroblast growth factor) activation of RTK, which is mediated by class I A isoforms, PI3Ka/b (and their downstream pathways). 4, 12, 15, 64, 66, 95 In contrast, loss of GPCR-coupled class I B isoform, PI3Kg does not alter basal heart/cardiomyocyte size and leaves stimulation of class I A -dependent RTK intact in cardiac fibroblast 4 and cardiomyocytes 15 while disrupting the activation of Akt/PKB (and MAPK pathways) by GPCR agonists. 12, 15, 71 Consistent with distinct roles of PI3K isoforms, loss of PI3Kg is associated with increased myocardial contractility, 12 whereas the inhibition of PI3Ka/b does not affect basal myocardial contractility.
12,66 PTEN negatively regulates both class I A and class I B basal PI3K signalling, leading to an uncoupling between structure (hypertrophy) and function (contractility) consistent with spatially restricted signalling mediated by PI3K isoforms in the heart ( Figure 1A) . 12 Loss of PTEN induces both myocardial hypertrophy and impaired myocardial contractility, whereas expressing DN-p110a abolishes the increased phospho-Akt/PKB and myocardial hypertrophy but retains the reduction in myocardial contractility ( Table 1) . 12 In contrast, mice lacking both PTEN and p110g in the heart maintained increased phospho-Akt/PKB levels and myocardial hypertrophy but with a hypercontractile state. 12 However, cross-talk between class I A and class I B isoforms may occur, such as the transactivation of RTK via intracellular Src tyrosine kinase or through MMP activation, which releases heparin-bound epidermal growth factor in the extracellular (interstitial) compartment. 4 The precise basis for this PI3K class-specific signalling is unclear but may be related to their mechanism of activation and negative regulation by lipid phosphatase(s). Agonistmediated activation of class I A PI3K appears to be highly spatially restricted via localized intracellular tyrosine autophosphorylation. 6, 95 The p110g catalytic subunit is clearly distinct from p110a/b owing to its lack of a C-terminus-binding domain for a member of the p85 adaptor family and therefore does not associate with p85 adaptor subunits. 4, 7, 13 Tyrosine-phosphorylated peptides which are able to activate PI3K class I A family members have no detectable effect on the PI3K class I B isoform, p110g. 13 Spatially localized signalling by PTEN (and other lipid phosphatases) may be mediated by their unique protein-interacting domains 7 or arise from PTEN being confined to specialized signalling regions such as lipid rafts. 96 PTEN is also regulated by PtdIns-mediated phosphorylation of PTEN, possibly via Akt/PKB, which decreases PTEN degradation, thereby serving as a negative feedback regulator of PI3K. 97 On the other hand, RTK and GPCR stimulate Src kinase, which phosphorylates PTEN, leading to reduced stability as well as inhibition of its phosphatase activity. 98 6. Role of phosphoinositide 3-kinase and PTEN in myocardial preconditioning and ischaemiareperfusion injury Ischaemic preconditioning (IPC) refers to a phenomenon where brief periods of mild ischaemia can protect the heart from subsequent ischaemia. Acute IPC lasts 2 h, and a second window of protection (i.e. delayed IPC) develops 24 h later and lasts 3 days. 99, 100 Preconditioning involves the release of several autacoids that trigger protection by activating various receptors, cell signalling cascades, and effectors. 99 ,100 PI3K/Akt and several downstream pathways are activated in myocardial ischaemia/ reperfusion. [99] [100] [101] Gene expression analysis of human ventricular myocardium in response to reversible myocardial ischaemia-reperfusion revealed an immediate genomic response characterized by the activation of multiple signalling pathways regulated by the PI3K system. 102 In acute IPC, there is increased phosphorylation of Akt/PKB, whereas PI3K inhibitors, wortmannin and LY294002, block reductions in infarct size, improvement in post-ischaemic function, and increases in phospho-Akt/PKB. 99, 100, 103 Acute PI3K inhibition also blocked reductions in infarct size and the associated increase in phosphoryation of PDK1 and Akt/PKB observed with delayed IPC. 100, 104 The precise connection between Akt/PKB activation and protection induced by IPC is unclear but may be related to enhanced cell survival and shifts in metabolism induced by Akt/PKB stimulation and/ or inhibition of GSK3b in response to phosphosphorylation. 4, 50, 100, 105 Accumulation of activated Akt/PKB in the mitochondria may also trigger additional protective mechanisms such as opening of mitochondrial K ATP channels. 99 Interestingly, cardiac-specific knockout of PDK-1 is associated with enhanced sensitivity to hypoxia, 34 whereas rapamycin, an inhibitor of mTOR, blocks delayed IPC. 100, 104 Animal models with increased class I A PI3K and/or Akt/ PKB signalling have enhanced cell survival and smaller infarct size in ischaemia-reperfusion. 4, 48, 106 Both RTK (e.g. insulin, IGF-1) and GPCR (e.g. adenosine, acetylcholine, opioid, and bradykinin) agonists can induce cardioprotective effects in IPC consistent with the possible role of Akt/PKB and other downstream signalling pathways. 50, 99, 100, 106 In response to ischaemia-reperfusion, loss of PI3Kg results in reduced phosphorylation of Akt/PKB and GSK3b, impaired functional recovery, and increased cell death, in addition to mitigating the protective effects of adenosine. 101 In contrast, PI3KaDN hearts responded in a 'preconditioned' manner owing to increased signalling via the other PI3K isoforms such as PI3Kg, resulting in enhanced phosphorylation of Akt/PKB and GSK3b, better functional recovery, and reduced cell death. 101 These results provide strong evidence for a pivotal role of GPCR-mediated activation of the PI3K signalling in IPC. Similarly, ischaemic postconditioning mediates cardioprotection in the remodelled rat myocardium primarily via the activation of the PI3K-PKB/Akt reperfusion injury salvage kinase pathway, 107 whereas erythropoietinmediated reduction in myocardial ischaemia-reperfusion injury is mediated in part by activation of the Akt/PI3K system. 108 Loss of PTEN activity due to reactive oxygen species-mediated degradation of PTEN leads to early Akt/ PKB activation and induction of IPC, whereas delayed feedback mechanisms restore PTEN levels, leading to the decay of IPC. 109 Consistent with the role of PTEN as a negative regulator of PI3K signalling, PTEN haploinsufficiency is sufficient to reduce the threshold of protection induced by IPC in association with increased phospho-Akt/PKB levels. 110 Collectively, these observations highlight the involvement of PI3K isoforms in different aspects of IPC and the potential use of selective modulation of PI3K signalling in optimizing protection from myocardial ischaemia/reperfusion.
7. Role of phosphoinositide 3-kinase and PTEN in heart failure PI3K/Akt and several downstream pathways are activated in heart disease including diabetic cardiomyopathy, 111 adriamycin-induced cardiomyopathy, 62, 112 chronic b-AR stimulation, 15, 71 pressure-overload-induced hypertrophy, 65, 67, 71 or in advanced human heart failure. 4, 92 Class I A and I B PI3K isoforms appear to have distinct roles in the pathogenesis of heart disease. Activation of PI3Ka in the heart during chronic exercise training is important for maintaining cardiac structure and function in the setting of pathological hypertrophy and may underlie the beneficial effects of exercise in patients with heart failure. 69 Furthermore, mesenchymal stem cells overexpressing Akt/PKB prolonged cardiomyocyte survival, prevented remodelling, and improved cardiac performance in infarcted hearts. 113 Cardiac-specific overexpression of DN-PI3Ka, knockout of the insulin receptor, and Akt1/PKBa accelerate the progression to dilated cardiomyopathy in response to GPCR stimulation and/or pressure-overload, which may be related to reduce phospho-Akt/PKB and cell survival, and/ or altered mechanotransduction. 4, 42, 66, 90 In addition, enhanced nuclear phospho-Akt/PKB is associated with delayed cellular ageing and death in cardiomyocytes, and phospho-Akt/PKB is higher in cardiomyocytes from adult premenopausal women compared with men or postmenopausal women, which may explain some of the age-related and gender-dependent differences in susceptibility to cardiovascular diseases. 4, 43, 113 PI3Kg activation has been linked with left ventricle enlargement and decompensation in pressure-overload-induced heart disease, suggesting that impaired PI3Kg signalling may have therapeutic benefits in experimental models of heart failure. 4, 65, 67 Loss of PI3Kg prevents isoproterenolinduced increases in cardiac Akt/PKB activity and ERK1/2 phosphorylation, resulting in reduced hypertrophy and preserved heart function. 4, 15 Increased PTEN expression associated with sustained b-adrenergic stimulation may serve to negate b-adrenergic receptor-mediated increases in PI3K activity. 15, 31 On the other hand, b-AR and angiotensin II-mediated Akt/PI3Kg and MAPK activation in cardiac fibroblasts may result in remodelling of the myocardial extracellular matrix as commonly seen in heart failure. 4, 15, 114 On the basis of the ability of PI3Kg in mediating negative inotropic effects of G ai signalling and excitation-contraction coupling, inhibiting PI3Kg may provide an important means to negate the increased G ai and/or to restore impaired Ca 2þ cycling in heart failure. 4, 12, 72, 74, 76, 77 Moreover, since several downstream pathways of PI3K signalling including GSK3b 4,53 and mTOR 58 are also altered in heart disease, targeting these pathways may also provide clinical benefit in the treatment of pathological hypertrophy and heart failure.
Despite the well-defined role of PI3Kg in GPCR signalling, excitation-contraction coupling, and pathological hypertrophy, recent evidence using the PI3Kg knockout mice has produced discordant findings in experimental models of heart failure. The key role of PI3Kg in minimizing myocardial ischemia-reperfusion injury 101 and in the recruitment of EPCs to ischaemic regions 18 suggests that loss of PI3Kg should result in worsening heart function in response to chronic myocardial ischaemic injury. However, in response to myocardial infarction, adverse ventricular remodelling and ventricular function in PI3Kg knockout mice did not differ from wildtype mice, 115 suggesting that responses controlling acute myocardial ischaemic reperfusion injury are distinct from those mediating long-term remodelling following myocardial infarction. In addition, although PI3Kg knockout mice are protected from isoproterenol-induced heart failure, 15 pressure-overload induced by aortic constriction in PI3Kg knockout mice leads to a rapid cardiac dilation and dysfunction compared with wild-type controls. 67, 72 These results highlight a potential role of PI3Kg in cell adhesion and mechanotransduction, which, if compromised, may result in adverse ventricular remodelling in response to biomechanical stress. 4, 23 Consistent with these observations, titin isoform transitions are mainly regulated through PI3K/Akt-dependent signalling triggered particularly by 3,5,3
0 -triiodo-L-thyronine via a rapid action pathway and is a major determinant of the extracellular matrix stiffness. 116 Despite baseline reduction in myocardial contractility, loss of PTEN prevents the development of maladaptive ventricular remodelling with preservation of angiogenesis and metabolic gene expression in response to pressure-overload, suggesting that inhibition of PTEN signalling in the heart may represent a novel approach to slow the progression of heart failure in response to pathological biomechanical stress ( Figure 1C) . 23 The pro-angiogenic effects associated with loss of PTEN and activation of PI3K signalling are consistent with a critical role of PI3Ka in endothelial migration and angiogenesis. 117 The uncoupling between basal myocardial contractility and the ability to tolerate pathological biomechanical stress strongly suggest that there are unique determinants of the cardiac response to pressure-overload, such as the cardiomyocyte-fibroblast-ECM adhesion network ( Figure 1C) . 23 
Future perspectives
The clearest evidence that our understanding of the PI3K system is suboptimal is the emerging trend of the uncoupling between PI3K cellular effects and those seen using in vivo models of heart disease, such as pressure-overload and myocardial infarction in PI3K mutant models, suggesting that PI3K signalling has many unexplored roles such as in cardiac mechanotransduction and metabolism. In view of what we have learnt so far, a major open question to be addressed is the residual role of PI3Kb in cardiac signalling and heart disease, and the recent availability of the PI3Kb knockout mice is a major step in the right direction. The availability of isoform-specific blockers of the PI3K system also provides a useful research tool to examine the shortterm effects of isoform-specific PI3K signalling. The GSK3 system has also emerged as a major downstream effector of the PI3K system, and the use of genetic knockin and cardiac-specific knockout of GSK3a and GSK3b isoforms will provide useful insight into their role in cardiac structure and function. Given the critical role of PI3K/GSK3 system in the cardiovascular system, the possibility of using PI3K isoform-specific and/or GSK3b inhibitors for a variety of medical conditions must be closely monitored for cardiovascular toxicity in order to avoid the many pitfalls encountered by several recent pharmaceutical therapeutic agents. 
